Advertisement

Topics

Nemus Bioscience Signs Development Agreement With Nanomerics To Advance Ocular Formulation Of NB1111 For The Treatment Of Glaucoma Using Proprietary Molecular Envelope Technology (MET)

20:00 EDT 19 Mar 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Nemus Bioscience Signs Development Agreement With Nanomerics To Advance Ocular Formulation Of NB1111 For The Treatment Of Glaucoma Using Proprietary Molecular Envelope Technology (MET)

NEXT ARTICLE

More From BioPortfolio on "Nemus Bioscience Signs Development Agreement With Nanomerics To Advance Ocular Formulation Of NB1111 For The Treatment Of Glaucoma Using Proprietary Molecular Envelope Technology (MET)"

Quick Search
Advertisement